TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily Compared to Fluticasone Propionate Delivered Twice Daily in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With High-strength Inhaled Corticosteroids or Mid-strength ICS/LABA Combination Therapy.
Brief Summary: A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with high-strength inhaled corticosteroids or mid-strength ICS/LABA combination therapy


Options:
A: Arm Label: ADVAIR 100/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 100/50mcg | Arm Label: ADVAIR 250/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 250/50mcg | Arm Label: FLOVENT 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 100mcg | Arm Label: FLOVENT 250mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 250mcg | Intervention Type: DRUG; Name: ADVAIR 100/50mcg; Assigned to Arm(s): ADVAIR 100/50mcg | Intervention Type: DRUG; Name: ADVAIR 250/50mcg; Assigned to Arm(s): ADVAIR 250/50mcg | Intervention Type: DRUG; Name: FLOVENT 100mcg; Assigned to Arm(s): FLOVENT 100mcg | Intervention Type: DRUG; Name: FLOVENT 250mcg; Assigned to Arm(s): FLOVENT 250mcg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort pMDI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide pMDI | Intervention Type: DRUG; Name: Symbicort pMDI; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide pMDI; Assigned to Arm(s): 2
C: Arm Label: FF/VI 200/25mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: GW685698/GW642444 | Arm Label: Fluticasone propionate 500mcg twice daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: CCI18781 | Intervention Type: DRUG; Name: GW685698/GW642444; Assigned to Arm(s): FF/VI 200/25mcg once daily | Intervention Type: DRUG; Name: CCI18781; Assigned to Arm(s): Fluticasone propionate 500mcg twice daily
D: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily for 12 Weeks in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With Low to Mid-strength Inhaled Corticosteroid or Low-strength Combination Therapy.
Brief Summary: A randomised, double-blind, placebo-controlled, parallel group multicentre study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily for 12 weeks in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with lowe to mid-strength inhaled corticosteroid or low-strength combination therapy.


Options:
A: Arm Label: FF/VI 200/25mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: GW685698/GW642444 | Arm Label: Fluticasone propionate 500mcg twice daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: CCI18781 | Intervention Type: DRUG; Name: GW685698/GW642444; Assigned to Arm(s): FF/VI 200/25mcg once daily | Intervention Type: DRUG; Name: CCI18781; Assigned to Arm(s): Fluticasone propionate 500mcg twice daily
B: Arm Label: fluticasone furoate/vilanterol trifenatate; Type: ACTIVE_COMPARATOR; Interventions: Drug: GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate); Assigned to Arm(s): fluticasone furoate/vilanterol trifenatate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: FF/VI; Type: EXPERIMENTAL; Interventions: Drug: FF/VI | Arm Label: Existing Maintenance Therapy; Type: OTHER; Interventions: Other: Existing Maintenance Therapy | Intervention Type: DRUG; Name: FF/VI; Assigned to Arm(s): FF/VI | Intervention Type: OTHER; Name: Existing Maintenance Therapy; Assigned to Arm(s): Existing Maintenance Therapy
D: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Arm Label: arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): arm 2 | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy
Brief Summary: To evaluate the long term effectiveness of Levetiracetam (LEV) monotherapy on Treatment Failure Rate in subjects with newly diagnosed partial onset seizures with or without secondary generalized seizures, compared to Oxcarbazepine (OXC) monotherapy over 50 weeks from the first dose


Options:
A: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Oxcarbazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxcarbazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Oxcarbazepine; Assigned to Arm(s): Oxcarbazepine
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): 1
C: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Older Antepileptic Drugs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine Controlled Release (CBZ-CR), Drug: Valproate Extended Release | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine Controlled Release (CBZ-CR); Assigned to Arm(s): Older Antepileptic Drugs | Intervention Type: DRUG; Name: Valproate Extended Release; Assigned to Arm(s): Older Antepileptic Drugs
D: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes
Brief Summary: Background: Preclinical blood pressure (BP) data from studies of hypoglycemic effects of liraglutide treatment (the LEAD program), revealed a significant antihypertensive potential. The time course and the mechanism behind this effect are unknown.

Objectives: To evaluate the time course of the antihypertensive effect of liraglutide treatment in patients with type 2 diabetes

Design: Open-label study with intervention and subsequent washout period

Patient Population: 35 hypertensive (SBP ≥130 mm Hg and DBP ≥80 mmHg) patients with type 2 diabetes.

Intervention: All patients will be treated with liraglutide 0.6 mg once daily for 7 days and will then be titrated to 1.2 mg once daily for 14 days and then titrated to 1.8 mg once daily for 4 weeks. This is followed by a washout period of 3 weeks without liraglutide treatment.

Endpoints: 24-hour blood pressure, natriuresis, extra cellular volume (ECV


Options:
A: Arm Label: Lorcaserin plus Lifestyle Modification; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorcaserin | Arm Label: Placebo plus Lifestyle Modification; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lorcaserin; Assigned to Arm(s): Lorcaserin plus Lifestyle Modification | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Lifestyle Modification
B: Arm Label: VI-0521 Top; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: VI-0521 Mid; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: VI-0521 | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Top | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Mid | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): Placebo
C: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide
D: Arm Label: Lorcaserin 10 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg once daily (QD) | Arm Label: Lorcaserin 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg twice a day (BID) | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo | Intervention Type: DRUG; Name: Lorcaserin 10 mg once daily (QD); Assigned to Arm(s): Lorcaserin 10 mg QD | Intervention Type: DRUG; Name: Lorcaserin 10 mg twice a day (BID); Assigned to Arm(s): Lorcaserin 10 mg BID | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia
Brief Summary: The purpose of this study is to evaluate whether ITI-007 is effective in reducing symptoms associated with schizophrenia in patients who are having an acute worsening of their psychosis. Patients will be randomly assigned to receive one of two doses of ITI-007, placebo, or a positive control. The primary goal will be to assess the effects of ITI-007 on psychosis. The safety of ITI-007 will also be assessed.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cariprazine 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 4.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Risperidone 4.0 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 1.5 mg, Cariprazine 3.0 mg, Cariprazine 4.5 mg | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone 4.0 mg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asenapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asenapine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo arm | Intervention Type: DRUG; Name: Asenapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asenapine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Placebo arm; Assigned to Arm(s): 4
C: Arm Label: LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): LY2140023 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: ITI-007 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: ITI-007, Drug: Placebo | Arm Label: ITI-007 High Dose; Type: EXPERIMENTAL; Interventions: Drug: ITI-007 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: ITI-007; Assigned to Arm(s): ITI-007 High Dose, ITI-007 Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): ITI-007 Low Dose, Placebo | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Towards a CARE AND WELFARE STANDARD for Community-dwelling Frail Elderly People With Complex Health Problems
Brief Summary: The purpose of this study is to investigate the effect of the CareWell-programme on overall functioning of community-dwelling frail elderly persons. Furthermore, the total costs and the cost-effectiveness of the CareWell-programme, in comparison with regular medical care, will be studied.


Options:
A: Arm Label: regular medical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: The CareWell programme; Type: EXPERIMENTAL; Interventions: Other: The CareWell programme | Intervention Type: OTHER; Name: The CareWell programme; Assigned to Arm(s): The CareWell programme
B: Intervention Type: BEHAVIORAL; Name: Geriatric Resources for Assessment & Care of Elders (GRACE); Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Dutch EASYcare Study Geriatric Intermediate Care Programme; Assigned to Arm(s): N/A
D: Arm Label: Conventional care, controlgroup; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: integrated health care chain; Type: EXPERIMENTAL; Interventions: Other: integrated health care chain | Intervention Type: OTHER; Name: integrated health care chain; Assigned to Arm(s): integrated health care chain

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Towards a CARE AND WELFARE STANDARD for Community-dwelling Frail Elderly People With Complex Health Problems
Brief Summary: The purpose of this study is to investigate the effect of the CareWell-programme on overall functioning of community-dwelling frail elderly persons. Furthermore, the total costs and the cost-effectiveness of the CareWell-programme, in comparison with regular medical care, will be studied.


Options:
A: Intervention Type: BEHAVIORAL; Name: Self-management of chronic illness; Assigned to Arm(s): N/A
B: Arm Label: Auto DAS; Type: EXPERIMENTAL; Interventions: Behavioral: Auto-DAS | Arm Label: Comorbidities treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Comorbidities treatment | Intervention Type: BEHAVIORAL; Name: Comorbidities treatment; Assigned to Arm(s): Comorbidities treatment | Intervention Type: BEHAVIORAL; Name: Auto-DAS; Assigned to Arm(s): Auto DAS
C: Arm Label: regular medical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: The CareWell programme; Type: EXPERIMENTAL; Interventions: Other: The CareWell programme | Intervention Type: OTHER; Name: The CareWell programme; Assigned to Arm(s): The CareWell programme
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Towards a CARE AND WELFARE STANDARD for Community-dwelling Frail Elderly People With Complex Health Problems
Brief Summary: The purpose of this study is to investigate the effect of the CareWell-programme on overall functioning of community-dwelling frail elderly persons. Furthermore, the total costs and the cost-effectiveness of the CareWell-programme, in comparison with regular medical care, will be studied.


Options:
A: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
B: Arm Label: Home Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Intel Health Guide | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Intel Health Guide; Assigned to Arm(s): Home Telemonitoring | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Self-management group workshops; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management group workshops | Arm Label: No treament (wait-list control); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-management group workshops; Assigned to Arm(s): Self-management group workshops
D: Arm Label: regular medical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: The CareWell programme; Type: EXPERIMENTAL; Interventions: Other: The CareWell programme | Intervention Type: OTHER; Name: The CareWell programme; Assigned to Arm(s): The CareWell programme

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Superficial Vein Thrombosis (SVT) Treated for Forty-five Days With Rivaroxaban Versus Fondaparinux
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus fondaparinux in the treatment of superficial vein thrombosis (SVT).


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux
B: Arm Label: Fondaparinux 2.5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Intervention Type: DRUG; Name: Fondaparinux 2.5mg or placebo; Assigned to Arm(s): Fondaparinux 2.5mg, Placebo
C: Arm Label: 1; Type: N/A; Interventions: Procedure: compression ultrasonography at 3 months | Arm Label: 2; Type: N/A; Interventions: N/A | Intervention Type: PROCEDURE; Name: compression ultrasonography at 3 months; Assigned to Arm(s): 1
D: Arm Label: dalteparin 5000 I.U./24 h s.c.; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Arm Label: dalteparin 15000 I.U./24 h s.c.; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): dalteparin 5000 I.U./24 h s.c. | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): dalteparin 15000 I.U./24 h s.c.

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy
Brief Summary: This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving MEC. Rolapitant or placebo will be administered prior to the initiation of chemotherapy on Day 1 with granisetron and dexamethasone. Subjects will record all events of emesis and the use of rescue medication for established nausea and/or vomiting, and will indicate the severity of nausea they experienced in each of the previous 24 hours in the Nausea and Vomiting (NV) Subject Diary prior to the MEC administration through Day 6 in Cycle 1. Health-related quality of life will be measured by the FLIE Questionnaire on Day 6 of Cycle 1. Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examination, electrocardiograms (ECGs), and safety laboratory values. All subjects are expected to complete Cycle 1 and will have the option of participating in up to five additional cycles.


Options:
A: Intervention Type: DRUG; Name: MK0869, aprepitant / Duration of Treatment: 3 days; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: ondansetron / Duration of Treatment: 4 days; Assigned to Arm(s): N/A
B: Arm Label: Netupitant and Palonosetron plus dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Netupitant and Palonosetron, Drug: Dexamethasone | Arm Label: Aprepitant and Palonosetron plus dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aprepitant, Drug: Palonosetron, Drug: Dexamethasone | Intervention Type: DRUG; Name: Netupitant and Palonosetron; Assigned to Arm(s): Netupitant and Palonosetron plus dexamethasone | Intervention Type: DRUG; Name: Aprepitant; Assigned to Arm(s): Aprepitant and Palonosetron plus dexamethasone | Intervention Type: DRUG; Name: Palonosetron; Assigned to Arm(s): Aprepitant and Palonosetron plus dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Aprepitant and Palonosetron plus dexamethasone, Netupitant and Palonosetron plus dexamethasone
C: Intervention Type: DRUG; Name: ONO-7436; Assigned to Arm(s): N/A
D: Arm Label: Placebo + Granisetron + Dexamethasone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Granisetron, Drug: Dexamethasone, Drug: Placebo | Arm Label: Rolapitant; Type: EXPERIMENTAL; Interventions: Drug: Rolapitant, Drug: Granisetron, Drug: Dexamethasone | Intervention Type: DRUG; Name: Rolapitant; Assigned to Arm(s): Rolapitant | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone, Rolapitant | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone, Rolapitant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone

Answer: D